Humacyte stock price target lowered to $3.50 at TD Cowen on mixed outlook

Humacyte (NASDAQ:HUMA) reported a significant Q2 2025 revenue shortfall of $301,000 against a $1.01 million consensus and a wider-than-expected loss per share, contributing to its stock being down over 73% year-to-date. This prompted varied analyst responses, with TD Cowen lowering its price target to $3.50 from $5.00 while maintaining a Buy rating, citing mixed Symvess commercial progress. However, TD Cowen and other firms noted improving recent commercial momentum, with July Symvess sales of $300,000 already exceeding total first-half 2025 product sales and increased hospital approvals, suggesting potential sequential revenue growth in the latter half of 2025 and into 2026 despite the current financial challenges.

Analysis

Humacyte (HUMA) is facing a critical juncture characterized by a stark contrast between its recent financial underperformance and emerging signs of commercial momentum. The company reported a significant second-quarter 2025 revenue shortfall, posting $301,000 against a consensus estimate of $1.01 million, coupled with a wider-than-expected loss per share of -$0.24 versus a -$0.16 forecast. This contributed to the stock's severe depreciation of over 73% in the past year. In response, several analysts, including TD Cowen and H.C. Wainwright, have lowered their price targets, citing the weak initial sales of its Symvess product. However, underlying bullish sentiment persists, as evidenced by maintained 'Buy' ratings. This optimism is fueled by tangible improvements in commercial traction; July product sales of approximately $300,000 have already exceeded total product sales for the first half of 2025. Furthermore, the number of hospital Value Analysis Committee approvals has increased from 5 in the first quarter to 13, suggesting an accelerating adoption curve. The wide dispersion of analyst price targets, ranging from $3.00 to $25.00, highlights the high degree of uncertainty surrounding the company's ability to convert these early positive signals into sustained revenue growth.

Key Decisions for Investors

• Investors should weigh the significant Q2 2025 revenue miss and historical stock underperformance against the recent, tangible signs of commercial acceleration for the Symvess product.
• The primary metric to monitor will be sequential revenue growth and new hospital committee approvals in the second half of 2025, which will serve as key validation for the bullish analyst theses.
• Given the stock's 73% decline and the wide analyst price target range, HUMA represents a high-risk, high-reward investment where near-term commercial execution is the dominant catalyst.